Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients in a mid-stage trial dropped out with high rates ...

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates ...

Pfizer's twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The ...

Pfizer stock fell Monday after the company announced it would pursue a twice-daily weight loss treatment pill in favor of its once-daily alternative amid a booming market for GLP-1 drugs.

Eli Lilly is also looking to enter the oral obesity space and is running a Phase III programme of its daily pill orforglipron. GlobalData predicts sales of orforglipron to reach $11.8bn in 2030.

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug.

Pfizer’s shares were up slightly more than 1% as its announcement to move forward with the development of the once-daily weight loss pill marks its comeback to the obesity space.

By TOM MURPHY (AP Health Writer) Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped tak… ...

Numerous drugmakers have been racing to develop oral versions of GLP-1 drugs for weight loss. After a setback, Pfizer says it has a viable candidate for a once-daily pill.

By TOM MURPHY (AP Health Writer) Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped ...

Pfizer’s shares were up slightly more than 1% as its announcement to move forward with the development of the once-daily weight loss pill marks its comeback to the obesity space.